^
    9ms
    A Clinical Study of MIL93 in Solid Tumors. (clinicaltrials.gov)
    P1, N=228, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    MIL93
    almost2years
    A Clinical Study of MIL93 in Solid Tumors. (clinicaltrials.gov)
    P1, N=228, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Feb 2023 --> Aug 2023
    Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    MIL93
    over2years
    Safety, tolerability, pharmacokinetics and preliminary efficacy of MIL93, an anti-Claudin18.2 monoclonal antibody, in patients with advanced solid tumors: A phase 1 clinical study. (ASCO 2022)
    MIL93 had a favorable safety profile with no DLTs observed through 20mg/kg Q3W. Pts with CLDN18.2-positive gastric cancer responded to the treatment. Dose escalation and expansion in selected tumor types is currently underway.
    Clinical • P1 data • PK/PD data
    |
    CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
    |
    CLDN18.2 positive
    |
    MIL93
    almost3years
    A Clinical Study of MIL93 in Solid Tumors. (clinicaltrials.gov)
    P1, N=228, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    MIL93